Tirzepatide: what the SURMOUNT and SURPASS trials actually measured

The short version

Tirzepatide is an FDA-approved prescription medicine. It is a synthetic peptide that activates two gut-hormone receptors — GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) — with a single weekly injection. Both receptors are involved in the body's response to food: they tell the pancreas to release insulin, tell the stomach to slow down, and tell the brain to feel full. Activating both at once appears to produce larger effects than activating one alone.

The FDA approved tirzepatide for type 2 diabetes in May 2022 and for chronic weight management in November 2023. In the largest weight-management trial (SURMOUNT-1, 2,539 participants), the 15 mg dose produced a mean body-weight reduction of 20.9% over 72 weeks, compared to 3.1% with placebo ^[4]. In a separate head-to-head trial against another approved GLP-1 medicine, tirzepatide produced an average loss of 20.2% versus 13.7% ^[5].

What people report — including the downsides such as nausea and the question of lean-mass loss — is on the Tirzepatide effects page.

What the SURMOUNT programme established

Tirzepatide has been evaluated in the largest dedicated obesity trial programme to date. SURMOUNT-1 (n=2,539, 72 weeks) produced mean weight changes of -15.0%, -19.5%, and -20.9% at the 5, 10, and 15 mg doses respectively, against -3.1% with placebo ^[4]. At the 15 mg dose, 57% of participants achieved at least 20% weight reduction — a threshold that had previously been attainable only with bariatric surgery.

SURMOUNT-3 (n=579) added tirzepatide after participants had already achieved ≥5% weight reduction through an intensive 12-week lifestyle programme. The additional mean weight change from that point was -18.4% with tirzepatide versus +2.5% with placebo over 72 weeks, a treatment difference of -20.8 percentage points ^[10].

SURMOUNT-5 (n=751) ran a head-to-head comparison: the maximum-tolerated dose of tirzepatide produced -20.2% body weight versus -13.7% with the maximum-tolerated dose of the approved GLP-1 comparator over 72 weeks (P<0.001) ^[5]. The tirzepatide group also achieved higher proportions reaching ≥10%, ≥15%, ≥20%, and ≥25% weight loss.

For Tirzepatide research on the glycaemic evidence, the mechanism, and the broader trial programme, see the evidence page.

FDA approval record and indications

Tirzepatide received FDA approval in three indications. The first (May 2022) covered adults with type 2 diabetes mellitus as an adjunct to diet and exercise ^[9]. The second (November 2023) covered chronic weight management in adults with a body mass index of ≥30 kg/m², or ≥27 kg/m² with at least one weight-related condition ^[9]. A subsequent approval followed for moderate-to-severe obstructive sleep apnea in adults with obesity, supported by the SURMOUNT-OSA trial ^[9].

The SURPASS programme evaluated tirzepatide across five phase 3 trials in type 2 diabetes. SURPASS-2 (n=1,879, 40 weeks) compared tirzepatide directly against an approved GLP-1 medicine: tirzepatide at 5, 10, and 15 mg reduced glycated haemoglobin (HbA1c — a blood marker of average glucose over approximately three months) by 2.01, 2.24, and 2.30 percentage points respectively, versus 1.86 percentage points with the comparator ^[3]. All three tirzepatide doses were noninferior and superior on the primary endpoint.

The compound is approved and prescription-only. It is not approved for type 1 diabetes. Tirzepatide references lists the full citation record.

Tirzepatide peptide: structure and pharmacokinetics

Tirzepatide peptide is a 39-amino-acid synthetic peptide built on the native GIP backbone, with a C20 fatty diacid (eicosanedioic acid) attached via a glutamic acid linker and two AEEA spacer units to a lysine side chain. The fatty-diacid arm binds albumin in the bloodstream, extending the elimination half-life to approximately five days — consistent with once-weekly subcutaneous dosing ^[1][7].

The compound's molecular formula is C₂₂₅H₃₄₈N₄₈O₆₈, molecular weight 4,813.53 Da (CAS 2023788-19-2, ATC A10BX16). Population pharmacokinetic modelling across the trial programme confirmed that the once-weekly profile is maintained across body weight ranges ^[7].

In vitro characterisation found tirzepatide engages the GIP receptor to a greater extent than the GLP-1 receptor — described as an 'imbalanced' dual agonist — and shows biased GLP-1 receptor signalling that preferentially activates the cAMP pathway over beta-arrestin recruitment (beta-arrestin normally dampens the insulin response) ^[2]. The clinical relevance of this receptor pharmacology profile, relative to balanced dual agonism, is still under investigation.

Subcutaneous injection is the only route in the approved and clinical-trial programme. See what is tirzepatide for a fuller structural account.

Tirzepatide results: what the primary outcomes showed

Tirzepatide results across the SURMOUNT and SURPASS programmes show consistent dose-dependent effects on both body weight and glycaemic markers. The figures cited here are from randomised controlled trials with placebo or active comparator arms.

On body weight: SURMOUNT-1 -20.9% (15 mg, 72 wk, n=2,539) ^[4]; SURMOUNT-3 additional -18.4% after lifestyle run-in (72 wk, n=579) ^[10]; SURMOUNT-5 -20.2% vs semaglutide -13.7% (72 wk, n=751) ^[5]. On HbA1c in type 2 diabetes: SURPASS-2 -2.30 percentage points (15 mg, 40 wk, n=1,879) vs -1.86 percentage points with comparator ^[3].

The SURMOUNT-OSA trial documented a reduction in the apnea-hypopnea index (the count of breathing interruptions per hour of sleep) alongside weight reduction in participants with obesity and moderate-to-severe obstructive sleep apnea ^[12]. The SURPASS-CVOT programme and dedicated trials in metabolic liver disease (SYNERGY-NASH) and heart failure with preserved ejection fraction (SUMMIT) contribute additional endpoints to the evidence base.

Weight regain after discontinuation is documented: the SURMOUNT-4 trial showed participants switched to placebo regained weight while those continuing tirzepatide continued to lose ^[13]. The SURMOUNT-4 post hoc analysis also showed cardiometabolic markers worsened with regain ^[14].